<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604576</url>
  </required_header>
  <id_info>
    <org_study_id>BRDEMS1011</org_study_id>
    <nct_id>NCT02604576</nct_id>
  </id_info>
  <brief_title>Efficacy of Bromopride and Simethicone Versus Bromopride in Functional Dyspepsia</brief_title>
  <official_title>Efficacy of Fixed-dose Combination of Bromopride and Simethicone Versus Isolated Bromopride in Participants With Functional Dyspepsia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, randomized, superiority, double blind clinical trial to asses the efficacy of
      fixed-dose combination of bromopride and simethicone versus isolated bromopride on research
      participants diagnosed with functional dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, randomized, superiority, double blind clinical trial to asses the efficacy of
      fixed-dose combination of bromopride and simethicone versus isolated bromopride in the relief
      os dyspepsia symptoms on research participants diagnosed with functional dyspepsia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms assessed by proportion of participants who have reduction equal to or greater than 50% in symptoms through questionnaire PADYQ</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety assessment will be performed by evaluating the incidence of adverse events in each group as well as the relationship of these events to the drug used, the amount and severity of reported events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDC Bromopride 10 mg and Simethicone 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bromopride 10 mg (Digesan ® - Sanofi Aventis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC Bromopride 10 mg and Simethicone 80 mg</intervention_name>
    <description>Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Bromopride 10 mg and Simethicone 80 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromopride 10 mg</intervention_name>
    <description>Bromopride 10 mg</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Digesan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent;

          -  Participants aged 18- 70 years;

          -  Clinical diagnosis of functional dyspepsia according to Rome III criteria;

          -  Minimum score of 22 points in PADYQ questionnaire

        Exclusion Criteria:

          -  Diagnosis of gastroesophageal reflux disease, irritable bowel syndrome, inflammatory
             bowel disease, gallstones, strongyloidiasis, giardiasis or ascariasis, clinical
             disease or significant psychological;

          -  Positive diagnosis for Helicobacter pylori;

          -  Clinically significant organic diseases in the HDE (High Digestive Endoscopy) prior to
             randomization;

          -  History of esophageal surgery, gastrointestinal or other intra-abdominal surgery;

          -  Hypersensitivity to the components of the formulations;

          -  Allergy tartrazine yellow dye;

          -  Allergy to aspirin;

          -  Use of PPIs, H2 blockers, prokinetics, antibiotics, prostaglandins or bismuth salts in
             the last week before the screening visit;

          -  Use of NSAIDs or aspirin more than two days a week (except AAS &lt;325mg / day), other
             drugs that induce gastrointestinal symptoms;

          -  Pregnant women or women without adequate contraception;

          -  Advance Participation in clinical trial protocols in the last twelve (12) months (CNS
             Resolution 251 of August 7, 1997, Part III, subsection J), unless the investigator
             considers that there may be direct benefit to it;

          -  Changes in hematological and biochemical tests: hemoglobin less than 12 g / dl,
             results with value 2 times the reference for AST, ALT, Gamma GT and alkaline
             phosphatase;

          -  Diagnosis of neurological or psychiatric diseases or decompensated diabetes;

          -  Use of drugs with anticholinergic action, narcotic analgesics, sedatives, hypnotics or
             tranquilizers;

          -  Alcoholism or sporadic use of alcohol and illicit drug use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Fernando Francesconi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto B. Amazonas, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Medicina Reprodutiva Carlos Isaia Filho Ltda</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Isaia Filho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Fernando Francesconi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ernesto Dornelles</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90160-092</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilherme B. Sander, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNIFAG</name>
      <address>
        <city>Bragança Paulista</city>
        <state>SP</state>
        <zip>129169000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Pedrazzoli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loema</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13010001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio R Santos, MD</last_name>
      <email>contato@loemaipc.com.br</email>
    </contact>
    <investigator>
      <last_name>Fabio R Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13060-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Francisco K. Saraiva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos Clínicos do Interior Paulista</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <zip>17201-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Tokunaga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>SP</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilson Catapani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AFIP</name>
      <address>
        <city>São Paulo</city>
        <state>Sâo Paulo</state>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edson Ide, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro A Crippa, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simethicone</mesh_term>
    <mesh_term>Bromopride</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

